The comprehensive Motor Neuron Disease content is maintained at the canonical disease page:
This page provides an in-depth overview of:
- Definition and classification: MND encompasses ALS, progressive bulbar palsy, primary lateral sclerosis, and progressive muscular atrophy
- Epidemiology: incidence ~1.5-3 per 100,000 person-years, prevalence ~4-8 per 100,000
- Clinical phenotypes: limb-onset (65-70%), bulbar-onset (25-30%), respiratory-onset (2-5%)
- Genetics: overlapping genetic architecture with frontotemporal dementia (C9orf72, TARDBP, FUS, SOD1)
- Pathogenesis: RNA metabolism dysfunction, protein aggregation, nucleocytoplasmic transport defects, mitochondrial dysfunction, excitotoxicity
- Neuropathology: TDP-43 inclusions (95% of ALS cases), FUS inclusions, SOD1 aggregates, Bunina bodies
- Diagnostic criteria: El Escorial revised criteria, Awaji criteria, Gold Coast criteria (2019)
- Management: multidisciplinary care, symptomatic treatment, respiratory support, nutritional management
Motor Neuron Diseases represent a group of disorders characterized by progressive degeneration of upper and/or lower motor neurons. The canonical page at /diseases/motor-neuron-disease contains detailed information and references from the primary literature.
This page has been consolidated into Motor Neuron Disease (MND). Content is maintained at the canonical page.